Dinuclear ruthenium complexes [(Ru(bid))2(μ‐bpp)(μ‐OAc)] and [(Ru(trpy))2(μ‐bpp)(μ‐X)]2+ [X=Cl−, OAc−, and OCHO−; bpp=3,5‐bis(2‐pyridyl)pyrazolato; bid−=(1Z,3Z)‐1,3‐bis(pyridin‐2‐ylmethylene)isoindolin‐2‐ide; trpy=2,2':6',2“‐terpyridine] were tested as catalysts for the hydrogenative reduction of carbon dioxide in the solvent 2,2,2‐trifluoroethanol in the presence of excess amine (triethylamine). Significant amounts of formic acid were produced by these catalysts, and a kinetic analysis based on initial rate constants was performed. These catalytic systems were investigated by using DFT calculations to elucidate the hydrogenative reduction mechanism. The results are compared with those obtained with previously reported mononuclear catalyst counterparts.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: